All times listed are Central Daylight Time. Program and Faculty are updated often – check back for the most up-to-date information. Click on session name to view session description and component talks.
2645: Age-specific Incidence of Systemic Lupus Erythematosus in the United States: A Meta-analysis of Data from the Centers for Disease Control and Prevention Lupus Registries
Location: W192A-C
Presenting Author: Peter Izmirly, MD – New York University Grossman School of Medicine
CE: 0.00
9:45 AM - 10:00 AM Central Time
2646: DNA methylation-based clustering reveals clinically distinct subtypes of systemic lupus erythematosus
Location: W192A-C
Presenting Author: Meghan Nelson, DO – National Institutes of Health
CE: 0.00
10:00 AM - 10:15 AM Central Time
2647: Unlinked Paths to SLE: Divergent Associations of DNA Methylation and Polygenic Risk Scores with SLE Features
2648: Transcriptome analysis of quiescent SLE cases uncovers dysregulated pathways associated with disease flares
Location: W192A-C
Presenting Author: Lorenzo Beretta, MD – Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano
CE: 0.00
10:30 AM - 10:45 AM Central Time
2649: Simultaneous Assessment of Complementary Lupus-Specific Immune Mediator-Informed Indexes Improves Their Ability to Concurrently Discern Current Disease Activity And Future Flare Risk In Systemic Lupus Erythematosus
2640: Effectiveness of Biological and Target-Synthetic Treatment in Patients with Rheumatoid Arthritis and Kidney Dysfunction: A Large Prospective Registry Study
Location: W190A-B
Presenting Author: Sho Fukui, MD, MPH – Brigham and Women's Hospital / Kyorin University Hospital
CE: 0.00
10:00 AM - 10:15 AM Central Time
2641: Cizutamig, a BCMA T-cell engager: preclinical to clinical translation of design optimization for the treatment of autoimmune diseases
2642: Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism: A Population-Based Cohort Study
What Causes Acinar Cell Dysfunction in Sjögren’s Disease? A Narrative Involving Fibroblast-mediated, Antigen-independent Activation of Tissue-resident CD8+ T-cells
2699: Cutaneous IgA Vasculitis: Emulation of a Target Trial from a European Multicentric Retrospective Study
Location: W187A-C
Presenting Author: Elena Biancamaria Mariotti, MD – University of Florence, Azienda USL Toscana Centro, Department of Dermatology, Florence
CE: 0.00
11:45 AM - 12:00 PM Central Time
2700: Neutrophil Transcriptomics and Maturation Pathways in VEXAS Syndrome
Location: W187A-C
Presenting Author: Benjamin Turturice, MD;PhD – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
CE: 0.00
12:00 PM - 12:15 PM Central Time
2701: Ophthalmic Manifestations of Relapsing Polychondritis
Location: W187A-C
Presenting Author: Akash Gupta, MD – Duke University School of Medicine
CE: 0.00
12:15 PM - 12:30 PM Central Time
2702: Diagnostic Performance of Vascular Ultrasound in Giant Cell Arteritis – A Single Center Experience
2703: Longitudinal Changes on Cranial Magnetic Resonance Imaging in Relapsing Giant Cell Arteritis
Location: W187A-C
Presenting Author: Ruoheng Zeng, BS – Perelman School of Medicine
CE: 0.00
12:45 PM - 1:00 PM Central Time
2704: Complete metabolic response on PET/CT in giant-cell arteritis-related large vessel vasculitis : comparison of two strategies using glucocorticoids or glucocorticoids + tocilizumab
2694: Effect of Deucravacitinib Treatment on Renal Dysfunction–Associated Plasma Biomarkers From a Phase 2 Study in Patients With Systemic Lupus Erythematosus
2696: Biomarker Data From an Open-Label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a Rapidly Manufactured CD19 CAR-T Therapy) Suggest Reset of the B Cell Compartment in Severe Refractory SLE
2697: A Prospective Randomized Controlled 96-week Study to Evaluate the Efficacy and Safety of Tacrolimus and Glucocorticoid as Continuous Induction-maintenance Treatment for Class III/IV±V Lupus Nephritis
2698: Comparative Efficacy of Tacrolimus-Based Induction Therapy with and without Mycophenolate Mofetil in Lupus Nephritis: A Target Trial Emulation Study
Location: W375C
Presenting Author: YUN KYU KIM, MD – Seoul National University
CE: 0.00
11:30 AM - 1:00 PM Central Time
29W15: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: Pathogenesis, Exercise, and Dietary Interventions (2687–2692)
Abstract Moderator: Jose Scher, MD – New York University School of Medicine
2687: Glucagon-like peptide-1 receptor agonists therapy is associated in improvement in psoriatic arthritis-related and metabolic outcomes: A retrospective analysis of two cohorts
2688: Single cell RNA-seq immune profiling of blood samples from a psoriatic disease clinical trial reveals a CD4 T cell population associated with response to IL-23 blockade
2689: Comparison of Incidence of Psoriatic Arthritis in Patients With Psoriasis Treated With Interleukin-17 Inhibitors vs Interleukin-23 Inhibitors, Interleukin-12/23 Inhibitors, and Tumor Necrosis Factor Inhibitors in Real-World Practice: A Retrospective Study
Location: W181A-C
Presenting Author: April Armstrong, MD, MPH – University of California Los Angeles, Los Angeles, CA, USA
CE: 0.00
12:15 PM - 12:30 PM Central Time
2690: Dietary interventions in Psoriatic Arthritis: A Randomized controlled clinical trial
2681: Derivation and Validation of Inflammation-Adjusted Lipid Measures to Improve Cardiovascular Risk Prediction in Rheumatoid Arthritis
Location: W183A-C
Presenting Author: Tate Johnson, MD – University of Nebraska Medical Center
CE: 0.00
11:45 AM - 12:00 PM Central Time
2682: Methotrexate use and higher age impair humoral response against the recombinant herpes zoster vaccine (RZV) in Rheumatoid Arthritis: a prospective, randomized, placebo-controlled trial
2683: Association of Genetic Risk for Pain Intensity with Longitudinal Disease Activity in Rheumatoid Arthritis
Location: W183A-C
Presenting Author: Stevie Barry, MBChB – University of Pennsylvania Health System Program
CE: 0.00
12:15 PM - 12:30 PM Central Time
2684: Multimodal Analysis Revealed Altered Brain Connectivity Patterns and Neuroinflammatory Processes in the Background of Difficult-To-Treat Rheumatoid Arthritis
2686: Impact of autoimmunity, disease activity and treatment on the time course of bone density, microstructure and biomechanics in inflammatory arthritis.
Location: W183A-C
Presenting Author: Koray Tascilar, MD – Friedrich Alexander University of Erlangen Nuremberg, Universitätsklinikum Erlangen Department of Medicine-3 Rheumatology and Immunology
CE: 0.00
11:30 AM - 1:00 PM Central Time
29W17: Abstracts: Pediatric Rheumatology – Clinical III (2675–2680)
2671: Effect of Efgartigimod PH20 SC on Total Improvement Score, its Core Set Measures, and Patient/Clinician Impressions of Change: Results from the Phase 2 ALKIVIA Study of Adults with Active Idiopathic Inflammatory Myopathy
2672: Safety and efficacy of Upadacitinib in melanoma differentiation-associated gene 5-positive dermatomyositis with interstitial lung disease: a single-centre, retrospective, propensity score-matched cohort study
29W19: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III: End Organ Focus on Heart, Lung and Eye (2663–2668)
Abstract Moderator: Lesley Ann Saketkoo, MD, MPH – University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris
29W19: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III: End Organ Focus on Heart, Lung and Eye
Location: W190A-B
Abstract Moderator: Lesley Ann Saketkoo, MD, MPH – University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris
2663: PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome
2665: Preexisting Antibodies Against Vaccine Antigens Are Preserved In Patients With Systemic Lupus Erythematosus and Sjögren’s Disease Upon Ianalumab Treatment While Autoantibodies Decline
2657: Incidence of Rheumatic Diseases Among Patients Receiving GLP-1 Receptor Agonists: A Comparative Analysis with DPP-4 Inhibitors in a Propensity Score-Matched Cohort
2658: Risk of Immune-Mediated Inflammatory Diseases and Other Safety Outcomes in Patients with T2DM and Obesity Initiating GLP-1 RA: A Propensity Score-Matched Multi-center Study using the TriNetX Global Network
2659: Sodium-Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Systemic Autoimmune Rheumatic Diseases in Patients with Type 2 Diabetes: A Population-Based Target Trial Emulation
Location: W184B-C
Presenting Author: Jamie Chieh Lo, MD – National Taiwan University Hospital
CE: 0.00
12:15 PM - 12:30 PM Central Time
2660: Understanding Gout in Women: Longitudinal Changes in Serum Urate Levels from Pre-menopause through Post-menopause
